Abstract: Sortilin is a sorting receptor that directs target proteins to the secretary or endocytic compartments of cells that is found in both extracellular vesicles and cells. Provided herein are methods and compositions for decreasing or inhibiting trafficking of sortilin to an extracellular vesicle, for example by inhibiting the formation of intermolecular sortilin dimers.

Abstract: Sortilin is a sorting receptor that directs target proteins to the secretary or endocytic compartments of cells that is found in both extracellular vesicles and cells. Provided herein are methods and compositions for decreasing or inhibiting trafficking of sortilin to an extracellular vesicle, for example by inhibiting the formation of intermolecular sortilin dimers.

Abstract: Compositions and methods for use in the treatment of disorders associated with aortic valve calcification. In some embodiments, the disorder is calcific aortic stenosis (CAS). Generally, the methods include administering a therapeutically effective amount of an inhibitor of MAOA as described herein, to a subject who is in need of, or who has been determined to be in need of, such treatment.

Abstract: The invention relates to methods for decreasing, inhibiting, preventing, or reducing calcification by inhibiting sortilin 1.

Abstract: The technology described herein is directed methods of treating an extracellular vesicle (EV)-associated disease or vascular calcification in subject by administration of an agent that reduces the levels or activity of Annexin A1 (ANXA1).

Abstract: The present invention is directed to methods of treating or preventing nonalcoholic fatty liver disease by administering agents that inhibit the NOTCH signaling pathway. Antibodies that inhibit the binding of Delta like 4 ligand (Dll4) to NOTCH receptors may be used for this purpose.

Abstract: Provided herein are methods for reducing levels of blood cholesterol, low-density lipoprotein (LDL), and/or the treatment of diseases associated with high cholesterol, hyperlipidemia, dyslipidemia, or high levels of low-density lipoprotein (LDL), wherein the methods comprise administering a DRP1 inhibitor to a subject in need thereof. In certain embodiments, the subject is selected for treatment as described herein when the subject exhibits intolerance to conventional statin therapy. Also contemplated herein are the use of DRP1 inhibitors in the treatment of cancer and inflammatory disease.

Abstract: Sortilin is a sorting receptor that directs target proteins to the secretary or endocytic compartments of cells that is found in both extracellular vesicles and cells. Provided herein are methods and compositions for decreasing or inhibiting trafficking of sortilin to an extracellular vesicle, for example by inhibiting the formation of intermolecular sortilin dimers.

Abstract: The technology described herein is directed to, e.g., methods of treating or preventing vascular calcification by modulating a novel calcification pathway which includes CROT, SLC20A1, PPAR?, HMOX1, STAT1, STAT3, and p38.

Abstract: The invention relates to methods for decreasing, inhibiting, preventing, or reducing calcification by inhibiting sortilin 1.

Abstract: The invention relates to methods for decreasing, inhibiting, preventing, or reducing calcification by inhibiting sortilin 1.

Abstract: Provided herein are methods for reducing levels of blood cholesterol, low-density lipoprotein (LDL), and/or the treatment of diseases associated with high cholesterol, hyperlipidemia, dyslipidemia, or high levels of low-density lipoprotein (LDL), wherein the methods comprise administering a DRP1 inhibitor to a subject in need thereof. In certain embodiments, the subject is selected for treatment as described herein when the subject exhibits intolerance to conventional statin therapy. Also contemplated herein are the use of DRP1 inhibitors in the treatment of cancer and inflammatory disease.

Abstract: Disclosed herein are compositions and methods for treating soft-tissue calcification by targeting SLC25A24 and/or SLC25A3.

Abstract: Embodiments herein provide for compositions and methods for inhibiting pathological endothelial-to-mesenchymal transition (EndMT), e.g., in endothelial cells and in a mammal. Specially, pathological EndMT can be inhibited by inhibiting CD45, either protein activity or protein expression or both, and optionally also inhibiting TGF-?. Compositions comprising a CD45 inhibitor, a CD45 inhibitor and a TGF-? inhibitor, or a CD45 inhibitor, a TGF-? inhibitor and an anti-fibrosis agent are disclosed.

Abstract: Systems and methods for imaging of matrix vesicle-derived calcification are described. In one embodiment, the method comprises raising the pH of collagen stored in a solution, thereby causing the collagen to come out of the solution to form a network, adding matrix vesicles to the network, resulting in calcifications, and imaging the formation of the calcification. The calcification process can be imaged in real time by confocal or reflected light microscopy.

Abstract: The present invention is directed to methods of treating or preventing nonalcoholic fatty liver disease by administering agents that inhibit the NOTCH signaling pathway. Antibodies that inhibit the binding of Delta like 4 ligand (Dll4) to NOTCH receptors may be used for this purpose.

Abstract: The invention relates to methods for decreasing, inhibiting, preventing, or reducing calcification by inhibiting sortilin 1.

Abstract: Disclosed herein are compositions and methods for treating soft-tissue calcification by targeting SLC25A24 and/or SLC25A3.

Abstract: The invention relates to methods for decreasing, inhibiting, preventing, or reducing calcification by inhibiting sortilin 1.

Abstract: The invention relates to methods for decreasing, inhibiting, preventing, or reducing matrix vesicle induced calcification by inhibiting the amount or formation of a complex comprising phosphatidylserine (PS), annexin II, annexin V or VI, and S100A9 or S100A12 in a macrophage.